Elektrofi develops innovative drug delivery technologies, particularly focusing on improving the stability and efficacy of injectable medications using their proprietary electrostatic stabilization method.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/08/2024 | Series C | $96.45MM | $xx.xx | $402.83MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
6,869,899
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/13/2022 | Series B | $42.55MM | $xx.xx | $131.18MM | Bvf Partners, Janus Henderson Investors, Logos Capital, Marshall Wace | |
Price per Share
$xx.xx
Shares Outstanding
7,247,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bvf Partners, Janus Henderson Investors, Logos Capital, Marshall Wace
|
||||||
06/30/2018 | Series A | $2.09MM | $xx.xx | $10.79MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,826,348
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/30/2018 | Series A-1 | $1.13MM | $xx.xx | $10.79MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
980,681
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|